Wednesday, March 02, 2022 10:00:24 PM
Why wouldn't it be needed?
One reason could be because of the amount of revenue we may raise through Clinigen.
But another reason could be because we may have produced about $300M in product beyond the company's stated goal of 100K treatments.
Possible OWS-type funding from France, the UK, and the US may also reduce our cash requirements.
So it makes sense to me that the company is not able to quantify the amount of equity funding, if any, they may need with another S-3.
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM